Sinovac Appoints New Chief Financial Officer

                 Sinovac Appoints New Chief Financial Officer

Vice President of Sinovac Named CFO

PR Newswire

BEIJING, May 31, 2013

BEIJING, May 31, 2013 /PRNewswire/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a
leading provider of biopharmaceutical products in China, announced today that
Ms. Nan Wang, Vice President of Sinovac, has been appointed as Chief Financial
Officer, effective June 1, 2013. Mr. Danny Chung, who was Chief Financial
Officer, has resigned for family reasons.

Since joining the Company in 2001, Ms. Wang has served in different senior
management roles inclusive of Vice General Manager of Sinovac Beijing, the
Company's primary operating subsidiary, former General Manager of Sinovac
Dalian, and as a member of the Board of Directors of Sinovac Beijing and
Sinovac Dalian. She oversees Sinovac's business development, strategic
management and investment. She was instrumental in leading the Company's
successful public offering in early 2010. Ms Wang previously served as Interim
CFO in 2011 before Mr. Chung joined the Company. She is actively involved in
the Company's investor relations activities. Ms. Wang received her Bachelor of
Science degree in Biology from Peking University and her Master of Business
Administration degree from the University of International Business and
Economics, Beijing PRC. She also holds a Diploma in Financial Management,
jointly issued by the Association of Chartered Certified Accountants (ACCA)
and Beijing College for Entrepreneurs.

Mr. Weidong Yin, Chairman, President and CEO, stated, "For more than twelve
years, Nan has served as a valuable member of Sinovac's senior management team
and developed a wealth of experience in the vaccine sector, communications
with investors, fundraising, and financial management. We believe her
business experience will bring additional value to the finance team as the
Company prepares to grow with the introduction of new products. On behalf of
the Board, we appreciate Danny's contributions to the Company and wish Danny
all the best in his future endeavors."

About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses
on the research, development, manufacturing and commercialization of vaccines
that protect against human infectious diseases including hepatitis A and B,
seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine
flu) and mumps, as well as animal rabies vaccine for canines. The Company
recently concluded the phase III clinical trial for enterovirus 71 (against
hand, foot and mouth disease). In 2009, Sinovac was the first company
worldwide to receive approval for its H1N1 influenza vaccine, Panflu.1, and
has manufactured it for the Chinese Central Government, pursuant to the
government-stockpiling program. The Company is also the only supplier of the
H5N1 pandemic influenza vaccine to the government-stockpiling program. Sinovac
is developing a number of new pipeline vaccines including vaccines for
pneumococcal polysaccharides, pneumococcal conjugate, varicella and rubella.
Sinovac sells its vaccines mainly in China and exports selected vaccines to
Mongolia, Nepal, and the Philippines. Sinovac has also been granted a license
to commercialize seasonal flu vaccine in Mexico.

Safe Harbor Statement
This announcement contains forward-looking statements. These statements are
made under the "safe harbor" provisions of the U.S. Private Securities
Litigation Reform Act of 1995. These forward-looking statements can be
identified by words or phrases such as "will," "expects," "anticipates,"
"future," "intends," "plans," "believes," "estimates" and similar statements.
Among other things, the business outlook and quotations from management in
this press release contain forward-looking statements. Statements that are not
historical facts, including statements about Sinovac's beliefs and
expectations, are forward-looking statements. Forward-looking statements
involve inherent risks and uncertainties. A number of important factors could
cause actual results to differ materially from those contained in any
forward-looking statement. Sinovac does not undertake any obligation to update
any forward-looking statement, except as required under applicable law.

Helen Yang/Chris Lee
Sinovac Biotech Ltd.
Tel: +86-10-8279-9659/9696
Fax: +86-10-6296-6910
Email: ir@sinovac.com

Investors:
Stephanie Carrington
The Ruth Group
Tel: +1-646-536-7017
Email: scarrington@theruthgroup.com

Media:
Aaron Estrada
The Ruth Group
Tel: +1-646-536-7028
Email: aestrada@theruthgroup.com

SOURCE Sinovac Biotech Ltd.

Website: http://www.sinovac.com
 
Press spacebar to pause and continue. Press esc to stop.